No scientific data to suggest Covid pills will be useful now: ICMR

The scientific data on anti-viral Covid pills still does not support that these medicines will be useful at the moment, ICMR Director General Balram Bhargava said

coronavirus, covid
A BMC health worker conducts thermal screening of an outstation passenger for Covid-19 testing, at Dadar Railway Station in Mumbai: Photo: PTI
IANS New Delhi
2 min read Last Updated : Dec 18 2021 | 7:51 AM IST

The scientific data on anti-viral Covid pills still does not support that these medicines will be useful at the moment as it has been found that they need to be given earlier even before the diagnosis of the disease, Indian Council of Medical Research Director General Balram Bhargava said on Friday.

In a briefing on the present situation of Covid and new variant Omicron in the country, he said that it is very important to have low-intensity festivities and avoid non-essential travel and mass gatherings.

Joint Secretary, Health, Luv Agrawal, said that new Covid cases are being reported below 10,000 for the past 20 days. The case positivity for the last 1 week was 0.65 per cent. Currently, Kerala contributes 40.31 per cent to the total number of active cases in the country, he said.

India is administering Covid-19 vaccine doses at the highest rate in the world and the daily rate of doses administered is 4.8 times the rate of doses administered in the US and 12.5 times the rate of doses administered in the UK, he said.

On new Covid variant, he said that a total of 101 Omicron cases across 11 states have been reported so far.

"There is no evidence to suggest that vaccines are not effective against Omicron variant," he said, adding that it is likely that Omicron will outpace Delta variant where community transmission occurs as per a WHO report.

NITI Aayog's Member, Health, Dr V.K. Paul said: "A new phase of the Covid-19 pandemic is being experienced in Europe with a steep rise in cases."

About genome sequencing, he said that sequencing of every sample is not possible.

"It is a surveillance and pandemic assessment and tracking tool, not a diagnostic tool as of now."

--IANS

avr/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusICMRhealth

First Published: Dec 18 2021 | 7:51 AM IST

Next Story